A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer

Piyush K. Agarwal, John P. Sfakianos, Adam Feldman, Scott T. Tagawa, Peter C. Black

Research output: Contribution to journalReview articlepeer-review

Abstract

The Urologic Oncology Journal was founded 25 years ago and we reviewed the literature since that time in the area of urothelial cancer to see the progress and pitfalls we have made over this time period. A comprehensive literature search was conducted by the authors involved who are all actively involved in research, clinical trials, and treatment for urothelial cancer and the results were summarized over the past 25 years. The field of urothelial cancer has evolved tremendously in the last 25 years with the incorporation of molecular subtyping, novel imaging, immunotherapy, and robotic surgery. However, treatments such as BCG and radical cystectomy have remained steadfast over the last 25 years. Although we have a better understanding of the biology of bladder cancer, we still have a long way from being able to cure patients with bladder cancer and eliminate morbidity from treatments. Nevertheless, considerable progress has been made since the founding of the Urologic Oncology Journal 25 years ago.

Original languageEnglish
Pages (from-to)528-547
Number of pages20
JournalUrologic Oncology: Seminars and Original Investigations
Volume39
Issue number9
DOIs
StatePublished - Sep 2021

Keywords

  • Bladder cancer
  • Chemotherapy
  • Immunotherapy
  • Radiation therapy
  • Review
  • Urothelial cancer

Fingerprint

Dive into the research topics of 'A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer'. Together they form a unique fingerprint.

Cite this